Search and analyze individual stocks with comprehensive metrics
Supriya Lifescience Ltd
Fundamental Score
Supriya Lifescience Ltd Share Price & Market Analysis
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of SUPRIYA across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Strong Return on Equity (20.75%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (27.46%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.
Strong Operating Margins (35.97%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.
Strong Revenue Growth (20.31%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.
Consistent Growth Track Record (17.45% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model and market opportunity execution over time.
Strong Profit Growth Track Record (20.71% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (131.31x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Balanced Promoter Holding (68.30%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
3 factors identified
Weak Earnings Growth (-14.16% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation. Consider growth catalysts and competitive positioning.
Negative Free Cash Flow (₹-56.28 Cr over 5Y)
Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.
Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Loading Peer Comparison
Finding companies in the Pharmaceuticals sector...
Financial Statements
Comprehensive financial data for Supriya Lifescience Ltd
About SUPRIYA
Company Details
Market Information
Performance
SUPRIYA Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of SUPRIYA?
SUPRIYA is currently trading at ₹756.30 with a gain of 0.00% today. The current market price (CMP) represents the last traded price of SUPRIYA shares on the stock exchange. This price fluctuates throughout trading hours based on supply and demand. You can track real-time price movements, percentage changes, and trading volume in the header section.
What is the P/E ratio of SUPRIYA and what does it mean?
SUPRIYA has a P/E ratio of 32.91x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹33 for every ₹1 of annual earnings. This is higher than the industry average, suggesting either growth premium or potential overvaluation.
How is SUPRIYA performing according to Bull Run's analysis?
SUPRIYA has a Bull Run fundamental score of 62.2/100, which indicates moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters including profitability (ROE: 20.75%), growth metrics, valuation ratios, and financial health indicators. The score updates quarterly with new financial data and helps you quickly assess overall investment quality.
What sector and industry does SUPRIYA belong to?
SUPRIYA operates in the Pharmaceuticals industry. This sector classification helps understand the broader economic trends, regulatory framework, and competitive landscape affecting Supriya Lifescience Ltd. Companies in this industry typically face similar market dynamics, cyclical patterns, and macroeconomic factors. Understanding the industry context is crucial for peer comparison and assessing how sector-specific trends might impact the stock's performance.
What is Return on Equity (ROE) and why is it important for SUPRIYA?
SUPRIYA has an ROE of 20.75%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently Supriya Lifescience Ltd generates profits from shareholders' equity. An ROE of 21% means the company generates ₹21 profit for every ₹100 of shareholders' equity. This metric is crucial for assessing management's ability to create value for shareholders.
How is SUPRIYA's debt-to-equity ratio and what does it indicate?
SUPRIYA has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk. This means the company has ₹0 of debt for every ₹100 of equity. This conservative approach provides financial stability but may limit growth potential.
What is SUPRIYA's dividend yield and is it a good dividend stock?
SUPRIYA offers a dividend yield of 0.13%, which means you receive ₹0.13 annual dividend for every ₹100 invested. The focus appears to be more on growth rather than dividend income. Dividend yield is calculated as annual dividend per share ÷ current share price × 100. Evaluate dividend consistency over 5+ years and free cash flow coverage for sustainability.
How has SUPRIYA grown over the past 5 years?
SUPRIYA has achieved 5-year growth rates of: Sales Growth 17.45%, Profit Growth 20.71%, and EPS Growth -14.16%. This consistent double-digit growth indicates a strong business model and competitive positioning. Sales growth indicates market expansion, profit growth shows operational efficiency, and EPS growth directly impacts share price appreciation potential.
What is the promoter holding in SUPRIYA and why does it matter?
Promoters hold 68.30% of SUPRIYA shares, with 0.00% of promoter shares pledged. This high promoter holding indicates strong management confidence and alignment with shareholders. Low pledging indicates financial stability of promoters. Recent change in promoter holding: 0.00%.
How does SUPRIYA compare with its industry peers?
SUPRIYA trades at P/E 32.91x vs industry average 31.77x, with ROE of 20.75% and ROCE of 27.46%. The stock trades at a premium to industry average, which may be justified by superior fundamentals. Peer comparison helps identify whether SUPRIYA is outperforming its competitive set in profitability, growth, and valuation metrics.
What is SUPRIYA's market capitalization and what category does it fall into?
SUPRIYA has a market capitalization of ₹6001 crores, making it a Large-cap stock. Large-cap stocks offer stability and liquidity but typically slower growth. Market cap is calculated as current share price × total outstanding shares, representing the company's total market value.
What are the key financial ratios to consider for SUPRIYA?
Key ratios for SUPRIYA: ROE 20.75% (Excellent), ROCE 27.46%, P/E 32.91x, Debt-to-Equity 0.00, Interest Coverage 131.31x. These ratios help assess profitability (ROE, ROCE), valuation (P/E), financial health (D/E, Interest Coverage), and overall investment quality. Compare these with industry medians and historical trends for meaningful analysis.
How volatile is SUPRIYA stock and what is its beta?
SUPRIYA has a beta of N/A, which means it is less volatile than the market and offers defensive characteristics. Beta measures price volatility relative to the Nifty 50. Lower beta stocks provide stability during uncertain market conditions. Consider beta alongside your risk tolerance and portfolio diversification strategy.
What is the 52-week high and low for SUPRIYA?
SUPRIYA has a 52-week high of ₹N/A and low of ₹N/A. Currently trading at ₹756.30, the stock is within its annual trading range. Trading near highs indicates strong momentum but limited upside potential.
What are the key risks associated with investing in SUPRIYA?
Key risks for SUPRIYA include: Market volatility (Beta: N/A), financial leverage (Debt-to-Equity: 0.00), and operational challenges. The stock has a Fundamental Score of 62.2/100, indicating moderate risk requiring careful monitoring. Sector-specific risks in Pharmaceuticals include regulatory changes, economic cycles, and competitive pressures. Consider your risk tolerance, investment horizon, and portfolio diversification before investing. Past performance doesn't guarantee future results.
What is SUPRIYA's operating profit margin and how has it trended?
SUPRIYA has a 5-year average Operating Profit Margin (OPM) of 35.97%, which is excellent and indicates strong pricing power and cost control. Operating Profit Margin shows operational efficiency by measuring operating profit as a percentage of revenue. This strong margin indicates competitive advantages and operational leverage. Compare with industry peers to understand relative performance.
How is SUPRIYA's quarterly performance in terms of sales and profit growth?
SUPRIYA's recent quarterly performance shows YoY Sales Growth of 20.31% and YoY Profit Growth of 9.27%. This shows decent growth momentum in the business. Sales growth shows market demand while profit growth reveals operational efficiency and margin management.
What is the FII and DII holding pattern in SUPRIYA?
SUPRIYA has FII holding of 5.46% and DII holding of 5.22%, totaling 10.68% institutional ownership. This institutional participation level shows the confidence of professional money managers. Monitor quarterly changes in institutional holdings for investment flow trends and sentiment.